We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
OPKO Health's growth outlook is supported by RAYALDEE, partner revenues and BioReference restructuring.
NGENLA is expanding globally, while mazdutide and Regeneron programs offer potential royalties and milestones.
BioReference is targeting breakeven as 4Kscore growth hinges partly on broader payer coverage and adoption.
OPKO Health, Inc. (OPK - Free Report) is well-positioned for growth in the coming quarters, supported by the potential of RAYALDEE. Optimism surrounding the stock is driven by RAYALDEE’s strong performance, strategic partnerships, BioReference restructuring and multiple pipeline catalysts. However, overdependence on RAYALDEE, early-stage clinical development risks and reimbursement uncertainties remain key concerns.
Shares of this Zacks Rank #3 (Hold) company have gained 30.1% in the year-to-date period, outperforming the industry's 5% decline and the S&P 500’s 12.5% rise.
This renowned multinational biopharmaceutical and diagnostics company has a market capitalization of $1.22 billion. OPK predicts 23.3% bottom-line growth for 2026 and anticipates maintaining its performance going forward. The company’s earnings surpassed estimates in three of the trailing four quarters and met in one, the average surprise being 95.09%.
Image Source: Zacks Investment Research
Factors Favoring OPK Stock
Strengthening Pharmaceutical Portfolio and Partner Revenues: OPKO Health’s pharmaceutical business is becoming an important contributor to growth. RAYALDEE remains the company’s principal proprietary commercial product, while international pharmaceutical operations are benefiting from stronger volumes. Pfizer’s NGENLA continues to expand globally, with OPKO receiving royalty and profit-share income as commercialization progresses. Management said that NGENLA is showing consistent growth as the market shifts away from daily growth hormone products.
OPKO is also building additional long-term value through partnered assets. Its agreement with Eli Lilly provides royalties on mazdutide, while the Regeneron collaboration gives ModeX an opportunity to generate future milestone payments and royalties if programs advance successfully.
BioReference Is Moving Toward a Leaner, More Focused Model: OPKO Health’s restructuring of BioReference has reduced the company’s exposure to lower-priority operations and left a more focused diagnostics business centered on its New York and New Jersey laboratory operations, correctional healthcare and the proprietary 4Kscore prostate cancer test. Management is targeting operating breakeven and sustainable profitability as the business becomes more efficient.
The 4Kscore franchise provides an additional growth avenue. Its expanded FDA label allows use without digital rectal examination information, broadening adoption among primary-care physicians. OPK is also pursuing broader payer coverage and physician education, which could support longer-term test volumes.
Pipeline and Strategic Transactions Offer Additional Upside: OPKO Health’s pipeline provides potential catalysts beyond its existing commercial portfolio. ModeX is advancing multispecific antibody programs, including an in vivo CAR-T approach that has generated encouraging preclinical data and is moving toward clinical development. The company is also developing OPK8801001, a once-weekly candidate for acromegaly, while collaborations with Regeneron and Entera expand its development opportunities.
OPK recently raised $125 million through senior secured notes backed by its mazdutide royalty interests. The financing provides non-dilutive capital while allowing the company to retain long-term participation in the royalty stream.
Factors That May Offset OPK’s Gains
Dependence on RAYALDEE and Commercialization Execution: Despite diversification efforts, RAYALDEE remains an important proprietary product for OPKO Health. Its future growth depends on prescription demand, pricing, reimbursement and successful expansion into additional markets. The amended Nicoya agreement provides OPK with an equity stake and potential milestones tied to RAYALDEE commercialization in Greater China, but regulatory approvals and commercial execution in the region remain ahead.
Early-Stage Pipeline Creates Clinical and Regulatory Risk: Several of OPKOHealth’s potentially valuable programs remain in development. ModeX’s in-vivo CAR-T technology and other candidates must still demonstrate safety and efficacy in clinical studies, while regulatory and development hurdles could delay commercialization or increase costs. The company itself cautions that potential milestones and royalties from partnered programs are subject to development and regulatory risks.
4Kscore Adoption and Reimbursement Remain Key Uncertainties: Although management sees substantial potential for 4Kscore, broader primary-care adoption depends partly on changes to Medicare requirements. On the second-quarter 2026 earnings call, management said it was taking a cautious approach until greater clarity from CMS, with significant impact coming from 2027 onward. This could delay the diagnostics business’ growth trajectory and its progress toward sustained profitability.
OPKO Health is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its loss per share has remained unchanged at 23 cents.
The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues and loss per share is pegged at $136.2 million and 7 cents, respectively. The estimate for revenues indicates a 10.2% fall from the year-ago quarter’s reported number, while that for loss implies a 333.3% decline.
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
Key Takeaways
OPKO Health, Inc. (OPK - Free Report) is well-positioned for growth in the coming quarters, supported by the potential of RAYALDEE. Optimism surrounding the stock is driven by RAYALDEE’s strong performance, strategic partnerships, BioReference restructuring and multiple pipeline catalysts. However, overdependence on RAYALDEE, early-stage clinical development risks and reimbursement uncertainties remain key concerns.
Shares of this Zacks Rank #3 (Hold) company have gained 30.1% in the year-to-date period, outperforming the industry's 5% decline and the S&P 500’s 12.5% rise.
This renowned multinational biopharmaceutical and diagnostics company has a market capitalization of $1.22 billion. OPK predicts 23.3% bottom-line growth for 2026 and anticipates maintaining its performance going forward. The company’s earnings surpassed estimates in three of the trailing four quarters and met in one, the average surprise being 95.09%.
Image Source: Zacks Investment Research
Factors Favoring OPK Stock
Strengthening Pharmaceutical Portfolio and Partner Revenues: OPKO Health’s pharmaceutical business is becoming an important contributor to growth. RAYALDEE remains the company’s principal proprietary commercial product, while international pharmaceutical operations are benefiting from stronger volumes. Pfizer’s NGENLA continues to expand globally, with OPKO receiving royalty and profit-share income as commercialization progresses. Management said that NGENLA is showing consistent growth as the market shifts away from daily growth hormone products.
OPKO is also building additional long-term value through partnered assets. Its agreement with Eli Lilly provides royalties on mazdutide, while the Regeneron collaboration gives ModeX an opportunity to generate future milestone payments and royalties if programs advance successfully.
BioReference Is Moving Toward a Leaner, More Focused Model: OPKO Health’s restructuring of BioReference has reduced the company’s exposure to lower-priority operations and left a more focused diagnostics business centered on its New York and New Jersey laboratory operations, correctional healthcare and the proprietary 4Kscore prostate cancer test. Management is targeting operating breakeven and sustainable profitability as the business becomes more efficient.
The 4Kscore franchise provides an additional growth avenue. Its expanded FDA label allows use without digital rectal examination information, broadening adoption among primary-care physicians. OPK is also pursuing broader payer coverage and physician education, which could support longer-term test volumes.
Pipeline and Strategic Transactions Offer Additional Upside: OPKO Health’s pipeline provides potential catalysts beyond its existing commercial portfolio. ModeX is advancing multispecific antibody programs, including an in vivo CAR-T approach that has generated encouraging preclinical data and is moving toward clinical development. The company is also developing OPK8801001, a once-weekly candidate for acromegaly, while collaborations with Regeneron and Entera expand its development opportunities.
OPK recently raised $125 million through senior secured notes backed by its mazdutide royalty interests. The financing provides non-dilutive capital while allowing the company to retain long-term participation in the royalty stream.
Factors That May Offset OPK’s Gains
Dependence on RAYALDEE and Commercialization Execution: Despite diversification efforts, RAYALDEE remains an important proprietary product for OPKO Health. Its future growth depends on prescription demand, pricing, reimbursement and successful expansion into additional markets. The amended Nicoya agreement provides OPK with an equity stake and potential milestones tied to RAYALDEE commercialization in Greater China, but regulatory approvals and commercial execution in the region remain ahead.
Early-Stage Pipeline Creates Clinical and Regulatory Risk: Several of OPKOHealth’s potentially valuable programs remain in development. ModeX’s in-vivo CAR-T technology and other candidates must still demonstrate safety and efficacy in clinical studies, while regulatory and development hurdles could delay commercialization or increase costs. The company itself cautions that potential milestones and royalties from partnered programs are subject to development and regulatory risks.
4Kscore Adoption and Reimbursement Remain Key Uncertainties: Although management sees substantial potential for 4Kscore, broader primary-care adoption depends partly on changes to Medicare requirements. On the second-quarter 2026 earnings call, management said it was taking a cautious approach until greater clarity from CMS, with significant impact coming from 2027 onward. This could delay the diagnostics business’ growth trajectory and its progress toward sustained profitability.
OPKO Health, Inc. Price
OPKO Health, Inc. price | OPKO Health, Inc. Quote
Estimate Trends of OPK
OPKO Health is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its loss per share has remained unchanged at 23 cents.
The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues and loss per share is pegged at $136.2 million and 7 cents, respectively. The estimate for revenues indicates a 10.2% fall from the year-ago quarter’s reported number, while that for loss implies a 333.3% decline.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.